Cantor Fitzgerald Brokers Lift Earnings Estimates for Pfizer

Pfizer Inc. (NYSE:PFE) – Research analysts at Cantor Fitzgerald lifted their FY2025 earnings per share (EPS) estimates for Pfizer in a report released on Wednesday, November 5th. Cantor Fitzgerald analyst C. Gould now expects that the biopharmaceutical company will post earnings of $3.20 per share for the year, up from their prior estimate of $3.05. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share. Cantor Fitzgerald also issued estimates for Pfizer’s FY2026 earnings at $3.25 EPS.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. The business had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS.

Several other analysts also recently issued reports on PFE. Morgan Stanley reduced their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a report on Friday, October 10th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Sanford C. Bernstein reiterated a “market perform” rating and set a $30.00 target price on shares of Pfizer in a report on Friday, October 31st. UBS Group reissued a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Finally, Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus target price of $28.18.

Pfizer Price Performance

Shares of NYSE PFE opened at $24.45 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company’s 50-day moving average price is $24.74 and its 200 day moving average price is $24.35. Pfizer has a 52 week low of $20.92 and a 52 week high of $27.69. The stock has a market cap of $138.99 billion, a price-to-earnings ratio of 13.00, a PEG ratio of 0.81 and a beta of 0.54.

Hedge Funds Weigh In On Pfizer

Large investors have recently bought and sold shares of the stock. GKV Capital Management Co. Inc. acquired a new stake in shares of Pfizer during the 1st quarter worth $27,000. Curio Wealth LLC grew its position in Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,098 shares during the period. Bayforest Capital Ltd acquired a new stake in Pfizer during the first quarter worth about $28,000. Harbor Asset Planning Inc. purchased a new position in shares of Pfizer in the 2nd quarter worth about $29,000. Finally, Grey Fox Wealth Advisors LLC purchased a new position in shares of Pfizer in the 3rd quarter worth about $29,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer’s payout ratio is presently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.